论文部分内容阅读
目的:研究双歧四联活菌多药联合对根除幽门螺杆菌(Helicobacter pylori,Hp)患者的临床疗效。方法:从2012年3月到2013年3月,共计60例病患因腹部不适就诊。以数字法随机分成实验组及对照组。对照组以埃索美拉唑镁肠溶片(剂量为20 mg bid)和胶体酒石酸铋钠(剂量为165 mg qid)以及克拉霉素片(剂量为0.5 bid)和阿莫西林胶囊(剂量为1.0 bid)等药物治疗。实验组则在对照组基础之上另以双歧四联活菌(剂量为1.5 tid)药物治疗。对比两组疗效和治疗后不良反应,以及治疗依从性情况。结果:实验组的根除率为86.67%(26/30),显著高于对照组的63.33%(19/30);未根除率为13.33%(4/30),显著低于对照组的36.67%(11/30)。实验组有不良反应者8例,占比26.67%,显著少于对照组的17例,占比56.67%;实验组在治疗后的依从性为好者占比90.00%(27/30),显著高于对照组的66.67%(20/30),依从性为差者占比10.00%(3/30),显著低于对照组的33.33%(10/30),差异均有统计学意义(均P<0.05)。结论:双歧四联活菌采用多药联合方式可明显提升对于Hp的根除率,同时减少不良反应,增加病患依从性。效果显著,值得临床推荐。
Objective: To study the clinical efficacy of multi-drug combination of bifidobacterium and tetramer in the treatment of patients with Helicobacter pylori (Hp). Methods: From March 2012 to March 2013, a total of 60 patients were treated for abdominal discomfort. Randomly divided into experimental group and control group by digital method. The control group was treated with esomeprazole magnesium enteric-coated tablets (20 mg bid) and sodium bismuth tartrate (165 mg qid) as well as clarithromycin tablets (0.5 bid) and amoxicillin capsules 1.0 bid) and other drug treatment. The experimental group was treated with bifidobacteria viable (1.5 tid) on the basis of the control group. The two groups were compared for efficacy and adverse reactions after treatment, and treatment compliance. Results: The eradication rate in the experimental group was 86.67% (26/30), significantly higher than 63.33% (19/30) in the control group. The eradication rate was 13.33% (4/30), significantly lower than that in the control group (36.67% (11/30). The experimental group had 8 cases of adverse reactions, accounting for 26.67%, significantly less than the control group of 17 cases, accounting for 56.67%; experimental group compliance after treatment for the good accounted for 90.00% (27/30), significant 66.67% (20/30) in the control group, 10.00% (3/30) in the compliance group, and 33.33% (10/30) in the control group, both of which were statistically significant P <0.05). Conclusion: Bifidobacterium quadriceps can improve the eradication rate of Hp, reduce the adverse reactions and increase the compliance of patients with multi-drug combination. The effect is remarkable, it is worth clinical recommendation.